3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035

  • ID: 4437255
  • Report
  • Region: Global
  • 350 Pages
  • Roots Analysis
10 % OFF
until May 20th 2018
1 of 5

FEATURED COMPANIES

  • 3D Bioprinting Solutions
  • Danske Bank
  • INSION
  • National Cancer Institute
  • Roche
  • University of Antwerp
  • MORE

3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues. For instance, in 2015, 3D Bioprinting Solutions became the first company to print and transplant a thyroid gland in a mouse. Subsequently, in the same year, Aspect Biosystems developed and commercialized 3D printed human respiratory tissue for clinical testing. In addition to these, other companies with commercialized tissue products include MEDPRIN, Poietis, and Sirris.

The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.

The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.

The ‘3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035’ report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting.

Amongst other things, the report features:

  • A detailed overview of the current market landscape of 3D bioprinters and 3D bioprinted products, highlighting the contributions of industry and non-industry players, including information on the various technological aspects and key specifications of such technologies / products.
  • Profiles of developers of bioprinting devices / technologies and bioprinted products. Each profile includes an overview of the company, information on their financials (wherever available), details on their respective product portfolios, 3D bioprinting specific collaborations, and an informed future outlook.
  • A comprehensive product competitiveness analysis of existing 3D bioprinters, based on supplier power and product specific features such as type of technology and range of applications.
  • An analysis of the partnerships that have been established in the recent past, covering research agreements, distribution agreements, product development agreements and other relevant deals, along with information on the collaborators / partners.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.
  • An analysis depicting the prevalent and emerging trends in 3D bioprinting as observed on the social media platform, Twitter. The report also includes a detailed case study on the upcoming trends, such as use of stem cells as bioinks, emergence of the concept of 4D bioprinting and commercialization of low-cost bioprinters, based on inputs from primary and secondary research.
  • An analysis of intellectual property portfolio related to 3D bioprinting. The study presents a high-level view on the granted patents and submitted patent applications related to these technologies, highlighting the prevalent trends in this domain. In addition, the analysis highlights the most active geographies and the key players driving innovation in this field.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, expected adoption rates and pricing, we have provided an informed estimate of the likely evolution of the opportunity within the market in the short to mid-term and long term, for the period 2018-2035. To account for the uncertainties associated with the development of 3D bioprinted products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Douglas Chrisey (Professor, Tulane University), Fanny Geraldo and Lisa Oliver (Researchers, University of Nantes), Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences), Igor Zlatkin (Application Scientist, Digilab), Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt), Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices), Lauralyn McDaniel (Industry Manager, SME), Marc Thurner (Chief Executive Officer, regenHU), Roger Narayan (Professor, North Carolina State University) and Simon Fried (Chief Business Officer, Nano Dimension). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • Over 70 bioprinters are currently either commercialized or under development; of these, close to 75% have been developed by industry players. Examples of commercialized 3D bioprinters by industry stakeholders include (in alphabetical order) 3D-Bioplotter® Series (EnvisionTEC), 3D Discovery® Series (regenHU), ALPHA-CP™ (SunP Biotech), Allevi 6 / BioBot 2 (Allevi / BioBots), BIO X (CELLINK), Fab@Home M4™ (Seraph Robotics) and Jetlab® 4-Larger Area (MicroFab Technologies).
  • Overall, more than 100 players, from both industry and academia, are currently focused on the development of 3D bioprinters and 3D bioprinted products. It is worth noting that several start-ups have emerged in the past five years; recent examples (in alphabetical order) include CELLINK, Flexadyne, Precise Bio, REGEMAT 3D, and Symme 3D. A significant proportion of startups are university spin-offs, including 3Dynamic Systems (Swansea University), Allevi (University of Pennsylvania), Aspect Biosystems (University of Columbia), Oxford MEStar (Oxford University) and Poietis (University of Bordeaux).
  • Around 60 research institutions are currently active in this field. In fact, close to 30% of the players are focused on developing their own 3D bioprinters; examples include (in alphabetical order), ClemsonUniversity, Heriot-Watt University, Ludwig Maximilian University of Munich (LMU), Medical University of South Carolina (MUSC), Nanyang Technological University (NTU), Technical University of Munich (TUM), University of Toronto, University of Wollongong and Wake Forest Baptist Medical Center.
  • Over 60% of the available bioprinters are based on the extrusion technology; examples include (in alphabetical order) ALPHA (3Dynamic Systems), Bio3D SYN^ (Bio3D Technologies), Bioscaffolder 3.1 (GeSim), Regenovo Bio-Printer (Regenovo Biotechnology) and UN-BIO-MINI / MINI Bio-printer (Qingdao Unique Products Develop). This is followed by inkjet-based bioprinters and laser-based bioprinters, which presently represent 26% and 2% of the total number of bioprinters, respectively. Apart from these, other types of technologies used in bioprinters include Kenzan technology, synQuad technology, piezoelectric nanoelectric pipetting and freeze-drying deposition mechanisms.
  • Several players are actively engaged in attempts to come up with new and innovative bioprinting techniques. This activity can be observed in the increasing number of patent applications filed related to 3D bioprinting. Of the total number of patents filed / granted from 1992 to late 2017, over 85% of the patents were filed in the last five years, beginning 2013.The US and China have emerged as global leaders in terms of intellectual property; these regions currently contribute to 37% and 27% of the filed patents, respectively.
  • The number of partnerships established annually over the past five years demonstrate an increasing trend; we identified close to 65 partnerships inked during the period 2012-2017. Majority of these partnerships are focused on R&D activities related to bioprinting technologies and products. Examples of recent research agreements include collaborations between Aether and University of South Australia (UniSA) (August 2017), GeSim and BellaSeno (August 2017), Trideo and Foundation for the Fight Against Infantile Neurological Diseases (FLENI) (May 2017), Symme3D and Center for Gene and Cellular Therapies in the Treatment of Cancer (OncoGen) (April 2017), and Aspect Biosystems and University of Manitoba (March 2017).
  • A variety of interesting trends, such as the development of bioinks in ready to print formats (by companies such as CELLINK) and introduction of the concept of 4D bioprinting (by companies such as Poietis), are emerging. In addition, several companies, for instance, Allevi (BioBots), BioCurious, Ourobotics, Seraph Robotics and SunP Biotech International, have undertaken efforts to develop low cost bioprinters. Multiple initiatives have also been launched to modify the existing 3D bioprinting techniques and come up with scaffold-free bioprinters.
  • As different products get approved for a diverse range of applications within the pharmaceutical / biotechnology market, we expect the market to witness a series of growth spurts across different applications, such as drug testing / drug screening, tissue engineering / tissue implants and organ transplants, in the coming years. Overall, we expect the 3D bioprinted products market to grow at an annualized rate of over 64% between 2018 and 2035.
  • Specifically, 3D printed organs for transplantation are expected to drive the long-term growth in this field; by 2035, we are led to believe that such organs have the potential to contribute to around 25% of the market’s share by 2035. North America and Europe are likely to maintain their dominance over the next decade. However, emerging regions, such as China, are expected to grow at a relatively faster rate as compared to the developed regions.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3D Bioprinting Solutions
  • Danske Bank
  • INSION
  • National Cancer Institute
  • Roche
  • University of Antwerp
  • MORE

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. Overview
3.2.2. Historical Evolution
3.2.3. 3D Printing in Medicine
3.3. 3D Bioprinting: Printing of Living Cells, Tissues and Organs
3.3.1. Historical Evolution
3.3.2. Process and Requirements
3.3.3. 3D Bioprinting Applications
3.3.3.1. Toxicity Screening / Drug Testing
3.3.3.2. Tissue Engineering
3.3.3.3. Organ Replacement
 
4. Market Landscape
4.1. Chapter Overview
4.2. 3D Bioprinting: Overall Market Landscape
4.2.1. 3D Bioprinters by Industry Players
4.2.1.1. Distribution by Geographical Location of Developers
4.2.1.2. Distribution by Founding Year of Developers
4.2.1.3. Distribution by Applications
4.2.1.4. Distribution by Cost of 3D Bioprinters
4.2.1.5. Distribution by Technology of 3D Bioprinters
4.2.1.6. Physical Features of 3D Bioprinters
4.2.1.7. Printing Parameters of 3D bioprinters
4.2.2. 3D Bioprinted Products by Industry Players
4.2.2.1. Distribution by Geographical Location of Developers
4.2.2.2. Distribution by Type of Product
4.3. 3D Bioprinters by Non-Industry Players
4.3.1. Distribution by Geographical Location of Developers
4.3.2. Distribution by Development Status
4.4. 3D Bioprinted Products by Non-Industry Players
4.4.1. Distribution by Geographical Location of Academia
4.4.2. Distribution by Type of Product
4.4.3. Distribution by Development Status
 
5. Company Profiles
5.1. Chapter Overview
5.2. 3Dynamic Systems
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.2.1. 3DS Alpha Bioprinter
5.2.2.2. 3DS Omega Bioprinter
5.2.2.3. Gel4Cell®
5.2.3. Recent Developments
5.2.4. Future Outlook
5.3. Aspect Biosystems
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.2.1. 3DAirwayALI™
5.3.2.2. 3DBioRing Airway™
5.3.2.3. RX1™
5.3.3. Awards and Accomplishments
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. Allevi (formerly BioBots)
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.2.1. Allevi 2 (BioBot 1)
5.4.2.2. Allevi 6 (BioBot 2)
5.4.3. Awards and Accomplishments
5.4.4. Future Outlook
5.5. BioDan Group
5.5.1. Company Overview
5.5.1.1. BioDan SkinMed
5.5.1.2. BioDan Sciences
5.5.1.3. BioDan Print
5.5.2. Recent Developments
5.5.3. Future Outlook
5.6. CELLINK
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.2.1. INKREDIBLE 3D Bioprinter
5.6.2.2. INKREDIBLE+ 3D Bioprinter
5.6.2.3. BIO X
5.6.2.4. Bioinks
5.6.3. Awards and Accomplishments
5.6.4. Recent Developments
5.6.5. Future Outlook
5.7. EnvisionTEC
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.2.1. 3D-Bioplotter® Starter Series
5.7.2.2. 3D-Bioplotter® Developer Series
5.7.2.3. 3D-Bioplotter® Manufacturer Series
5.7.3. Awards and Accomplishments
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. GeSiM
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.2.1. Bioscafolder 3.1 (BS3.1)
5.8.3. Recent Developments
5.8.4. Future Outlook
5.9. MEDPRIN BIOTECH
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.2.1. ReDura™
5.9.2.2. NeoDura™
5.9.3. Recent Developments
5.9.4. Future Outlook
5.10. microdrop Technologies
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.2.1. Autodrop Compact System
5.10.2.2. Autodrop Professional Positioning System AD-P-8000
5.10.3. Recent Developments
5.10.4. Future Outlook
5.11. MicroFab Technologies
5.11.1. Company Overview
5.11.2. Product Portfolio
5.11.2.1. JetLab® 4 Printing Platforms
5.11.2.2. JetLab® II-Precision
5.11.3. Awards and Accomplishments
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. Nano3D Biosciences
5.12.1. Company Overview
5.12.2. Product Portfolio
5.12.2.1. Magnetic 3D Bioprinting Technology
5.12.3. Recent Developments
5.12.4. Future Outlook
5.13. Organovo
5.13.1. Company Overview
5.13.2. Product Portfolio
5.13.2.1. NovoGen MMX™
5.13.2.2. ExVive™ 3D Bioprinted Human Liver Tissues
5.13.2.3. ExVive™ 3D Bioprinted Human Kidney Tissues
5.13.3. Preclinical Study Results
5.13.4. Awards and Accomplishments
5.13.5. Recent Developments
5.13.6. Future Outlook
5.14. Qingdao Unique Products Develop
5.14.1. Company Overview
5.14.2. Product Portfolio
5.14.2.1. 3D Bio-Printer
5.14.2.2. Anyprint B01CS
5.14.2.3. Bio-Membrane Printer
5.14.2.4. MINI Bio-Printer
5.14.2.5. Re-human
5.14.3. Recent Developments
5.14.4. Future Outlook
5.15. regenHU
5.15.1. Company Overview
5.15.2. Product Portfolio
5.15.2.1. 3D Discovery™
5.15.2.2. BioFactory™
5.15.2.3. OsteoInk™
5.15.2.4. Stark™
5.15.3. Awards and Accomplishments
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. SunP Biotech International
5.16.1. Company Overview
5.16.2. Product Portfolio
5.16.2.1. ALPHA-CP™ 21
5.16.2.2. ALPHA-BP™ 11
5.16.2.3. APLHA-CP™ 41
5.16.3. Future Outlook
 
6. Recent Collaborations and Funding
6.1. Chapter Overview
6.2. Partnership Models
6.3. 3D Bioprinting: Recent Collaborations
6.3.1. Analysis by Year of Collaborations
6.3.2. Analysis by Type of Collaborations
6.3.3. Most Active Companies: Analysis by Number of Collaborations
6.4. Venture Capital Interest
6.5. Types of Funding
6.6. 3D Bioprinting: Funding Instances
6.6.1. Analysis by Type of Funding Instance
6.6.2. Analysis by Number of Funding Instances
 
7. SWOT Analysis
7.1. Chapter Overview
7.2. Strengths
7.3. Weaknesses
7.4. Opportunities
7.5. Threats
 
8. Emerging Trends on Social Media
8.1. Chapter Overview
8.2. Trends on Twitter
8.3. Popular Keywords and Word Cloud Analysis
 
9. Recent Trends in 3D Bioprinting Industry
9.1. Chapter Overview
9.2 Introduction of Scaffold-Free Bioprinting
9.3 Emergence of 4D Bioprinting: the Next Generation of 3D Bioprinting
9.4 Use of Stem Cells as Bio Ink
9.5 Development of UV 3D Bioprinting, a Modified Stereolithography Approach
9.6 Establishment of Spin-Offs of Academic Institutes
9.7 Entry of Well-Established Players of 3D Printing Industry in Bioprinting Industry
9.8 Introduction of Low-Priced Bioprinters
9.9 Increasing Number of Initiatives Taken by Governments of Different Countries
 
10. Product Competitiveness Analysis
10.1. Chapter Overview
10.2. Scope and Methodology
10.3 3D Bioprinters: 2 x 2 Product Competitiveness vs. Supplier Power Analysis
 
11. Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. 3D Bioprinting Patents: Distribution by Publication Year
11.4. 3D Bioprinting Patents: Distribution by Geographical Location
11.5. 3D Bioprinting Patents: Distribution by CPC Classifications
11.6. 3D Bioprinting Patents: Emerging Areas
11.7. 3D Bioprinting Patents: Leading Players
 
12. Market Forecast and Opportunity Analysis
12.1. Chapter Overview
12.2. Forecast Methodology
12.3. Overall 3D Bioprinting Market, 2018-2035
12.4. 3D Bioprinting Market: Distribution by Applications
12.4.1. 3D Bioprinting Market for Drug Testing / Drug Screening
12.4.2. 3D Bioprinting Market for Tissue Engineering / Tissue Implants
12.4.2.1. 3D Bioprinted Skin
12.4.2.2. 3D Bioprinted Cornea
12.4.2.3. 3D Bioprinted Cartilage
12.4.2.4. 3D Bioprinted Bone
12.4.2.5. 3D Bioprinted Blood Vessels
12.4.2.6. 3D Bioprinted Heart Valves
12.4.3. 3D Bioprinting Market for Organ Transplants
12.4.3.1. 3D Bioprinted Breast Implants
12.4.3.2. 3D Bioprinted Kidney
12.4.3.3. 3D Bioprinted Liver
12.4.3.4. 3D Bioprinted Heart
12.5. 3D Bioprinting Market: Distribution by Region (North America, Europe, Asia Pacific and Rest of the World)
12.6. 3D Bioprinting Market: Distribution by Technology (Extrusion, Inkjet, Laser and Others)
 
13. Conclusion
13.1. 3D Bioprinting has Garnered Significant Attention within the Biopharmaceutical Industry
13.2. The Competitive Market Landscape Features a Mix of Industry and Non-Industry Players
13.3. North America and Europe Dominate the Current Market; Several Companies based in the Asia Pacific are also Making Notable Progress
13.4. Research Continues to be the Major Focus as Stakeholders Strive to Improve Existing Methods and Technologies
13.5. Increasing Partnership Activity and Financial Support from Public and Private Investors are Expected to Drive Growth
13.6. Recent Advances are Expected to Act as Catalyst to the Success of 3D Bioprinting
13.7. Inherent Challenges Must be Overcome to Tap the Multi-billion Dollar Opportunity in the Long Term
 
14. Interview Transcripts
14.1. Chapter Overview
14.2. Douglas Chrisey, Professor, Tulane University
14.3. Igor Zlatkin, Application Scientist and Chirantan Kanani, Technology & Product Development, Digilab
14.4. Fanny Geraldo and Lisa Oliver, Researchers, University of Nantes
14.5. Glauco R Souza, President & Chief Scientific Officer and Hubert Tseng, Senior Research Scientist, n3D Biosciences
14.6. Kenneth Church, President & Chief Executive Officer and Xudong Chen, Executive Vice President Business Development & Sales, nScrypt
14.7. Laura Bosworth, Chief Executive Officer & Co-Founder, TeVido BioDevices
14.8. Lauralyn McDaniel, Industrial Manager, SME
14.9. Marc Thurner, Chief Executive Officer, regenHU
14.10. Roger Narayan, Professor, North Carolina State University
14.11. Simon Fried, Chief Business Officer, Nano Dimension
14.12. Anonymous, MicroFab Technologies
 
15. Appendix 1: Tabulated Data

16. Appendix 2: List of Companies and Organizations

List of Figures
Figure 3.1 The Bioprinting Process
Figure 4.1 3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
Figure 4.2 3D Bioprinters by Industry Players: Distribution by Founding Year of Developers
Figure 4.3 3D Bioprinters by Industry Players: Distribution by Applications
Figure 4.4 3D Bioprinters by Industry Players: Distribution by Cost (USD)
Figure 4.5 3D Bioprinters by Industry Players: Distribution by Technology
Figure 4.6 3D Bioprinters by Industry Players: Distribution by Printer Weight
Figure 4.7 3D Bioprinters by Industry Players: Distribution by Number of Printheads
Figure 4.8 3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
Figure 4.9 3D Bioprinted Products by Industry Players: Distribution by Product Type
Figure 4.10 3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Academia
Figure 4.11 3D Bioprinters by Non-Industry Players: Distribution by Development Status
Figure 4.12 3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Academia
Figure 4.13 3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
Figure 4.14 3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
Figure 5.1 Organovo: Annual Revenues, 2011- 2017 (USD Million)
Figure 6.1 3D Bioprinting Collaborations: Distribution by Year, 2012-2017
Figure 6.2 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
Figure 6.3 3D Bioprinting Collaborations: Most Active Players, 2012-2017
Figure 6.4 3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
Figure 6.5 3D Bioprinting Funding Instances: Distribution by Total Amount Invested, 2012-2017 (USD Million)
Figure 6.6 3D Bioprinting Funding Instances: Most Active Players, 2012-2017
Figure 7.1 3D Bioprinting: SWOT Analysis
Figure 7.2 3D Bioprinting SWOT Analysis: Strengths
Figure 7.3 3D Bioprinting SWOT Analysis: Weaknesses
Figure 7.4 3D Bioprinting SWOT Analysis: Opportunities
Figure 7.5 3D Bioprinting SWOT Analysis: Threats
Figure 8.1 3D Bioprinting Social Media Analysis: Yearly Distribution of Tweets, January 2012-September 2017
Figure 8.2 3D Bioprinting Social Media Analysis: Popular Keywords on Twitter, January 2012 to September 2017
Figure 10.1 3D Bioprinters: Product Competitiveness Analysis
Figure 11.1 3D Bioprinting Patents: Distribution by Publication Type
Figure 11.2 3D Bioprinting Patents: Distribution by Publication Year
Figure 11.3 3D Bioprinting Patents: Distribution by Year and Regions
Figure 11.4 3D Bioprinting Patents: Distribution by CPC Classification Symbol
Figure 11.5 3D Bioprinting Patents: Emerging Areas
Figure 11.6 3D Bioprinting Patents: Leading Assignees
Figure 11.7 3D Bioprinting Patents: Geographical Distribution of Leading Assignees
Figure 12.1 3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.2 3D Bioprinting Market: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Figure 12.3 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035, Base Scenario (USD Billion)
Figure 12.4 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.5 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Figure 12.6 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Figure 12.7 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Figure 12.8 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario (USD Billion)
Figure 12.9 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Figure 12.10 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (Till 2035), Base Scenario (USD Billion)
Figure 12.11 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.12 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.13 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.14 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.15 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.16 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.17 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.18 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.19 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.20 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Base Scenario (USD Billion)
Figure 12.21 3D Bioprinting Market: Distribution by Region, (Till 2035), Base Scenario (USD Billion)
Figure 12.22 3D Bioprinting Market: Distribution by Technology, (Till 2035), Base Scenario (USD Billion)
Figure 13.1 3D Bioprinting Market: Key Drivers
Figure 13.2 3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)

List of Tables
Table 3.1 RepRap Project: 3D Printing Machines
Table 3.2 Inputs for 3D Bioprinting
Table 4.1 List of 3D Bioprinters by Industry Players
Table 4.2 3D Bioprinters by Industry Players: Bioprinting Technologies
Table 4.3 3D Bioprinters by Industry Players: Physical Features
Table 4.4 3D Bioprinters by Industry Players: Printing Parameters
Table 4.5 List of 3D Bioprinted Products by Industry Players
Table 4.6 List of 3D Bioprinters by Non-Industry Players
Table 4.7 List of 3D Bioprinted Products by Non-Industry Players
Table 5.1 3Dynamic Systems: Product Portfolio
Table 5.2 3Dynamic Systems: Technical Specifications of 3DS Alpha
Table 5.3 3Dynamic Systems: Technical Specifications of 3DS Omega
Table 5.4 Aspect Biosystems: Product Portfolio
Table 5.5 Aspect Biosystems: Technical Specifications of RX1™
Table 5.6 BioBots: Product Portfolio
Table 5.7 Allevi (BioBots): Technical Specifications of Allevi 2 (BioBot 1)
Table 5.8 Allevi (BioBots): Technical Specifications of Allevi 6 (BioBot 2)
Table 5.9 BioDan Group: Therapeutic Segments
Table 5.10 CELLINK: Product Portfolio
Table 5.11 CELLINK: Technical Specifications of INKREDIBLE 3D Bioprinter
Table 5.12 CELLINK: Technical Specifications of INKREDIBLE+ 3D Bioprinter
Table 5.13 CELLINK: Technical Specifications of BIO X
Table 5.14 CELLINK: Specifications of Bioinks
Table 5.15 EnvisionTEC: Product Portfolio
Table 5.16 EnvisionTEC: Consumables for 3D-Bioplotter® Bioprinters
Table 5.17 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Starter Series
Table 5.18 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Developer Series
Table 5.19 EnvisionTEC: Technical Specifications of 3D-Bioplotter® Manufacturer Series
Table 5.20 GeSiM: Product Portfolio
Table 5.21 GeSiM: Technical Specifications of BioScaffolder3.1
Table 5.22 MEDPRIN BIOTECH: Product Portfolio
Table 5.23 MEDPRIN BIOTECH: Technical Specifications of ReDura™
Table 5.24 microdrop Technologies: Product Portfolio
Table 5.25 microdrop Technologies: Technical Specifications of Autodrop Compact System
Table 5.26 microdrop Technologies: Technical Specifications of Autodrop Professional Positioning System AD-P-8000
Table 5.27 MicroFab Technologies: Product Portfolio
Table 5.28 MicroFab Technologies: Technical Specifications of JetLab®4
Table 5.29 MicroFab Technologies: Technical Specifications of JetLab® II-Precision
Table 5.30 n3D Biosciences: Product Portfolio
Table 5.31 Organovo: Product Portfolio
Table 5.32 Qingdao Unique Products Develop: Product Portfolio
Table 5.33 Qingdao Unique Products Develop: Technical Specifications of 3D Bio-Printer
Table 5.34 Qingdao Unique Products Develop: Technical Specifications of Anyprint B01CS
Table 5.35 Qingdao Unique Products Develop: Technical Specifications of Bio-Membrane Printer
Table 5.36 Qingdao Unique Products Develop: Technical Specifications of MINI Bio-Printer
Table 5.37 regenHU: Product Portfolio
Table 5.38 regenHU: Technical Specifications of 3D Discovery™
Table 5.39 regenHU: Technical Specifications of BioFactory™
Table 5.40 regenHU: Types and Details of ECM-BioInks™
Table 5.41 regenHU: Technical Specifications of OsteoInk™
Table 5.42 SunP Biotech International: Product Portfolio
Table 5.43 SunP Biotech International: Technical Specifications of ALPHA-CP™ 21
Table 5.44 SunP Biotech International: Technical Specifications of APLHA-BP™ 11
Table 5.45 SunP Biotech International: Technical Specifications of APLHA-CP™ 41
Table 6.1 3D Bioprinting: Recent Collaborations, 2012-2017
Table 6.2 3D Bioprinting: List of Funding Instances and Investors, 2012-2017
Table 6.3 3D Bioprinting: Types of Funding Instances, 2012-2017
Table 11.1 3D Bioprinting Patents: CPC Symbol Definitions
Table 11.2 3D Bioprinting Patents: Most Popular CPC Symbols
Table 11.3 3D Bioprinting Patents: List of Top CPC Classifications
Table 12.1 Expected Launch Timeline of 3D Bioprinted Products for Different Applications
Table 15.1 3D Bioprinters by Industry Players: Distribution by Geographical Location of Developers
Table 15.2 3D Bioprinters by Industry Players: Distribution by Founding Year of Developers
Table 15.3 3D Bioprinters by Industry Players: Distribution by Applications
Table 15.4 3D Bioprinters by Industry Players: Distribution by Cost (USD)
Table 15.5 3D Bioprinters by Industry Players: Distribution by Technology
Table 15.6 3D Bioprinters by Industry Players: Distribution by Printer Weight
Table 15.7 3D Bioprinters by Industry Players: Distribution by Number of Printheads
Table 15.8 3D Bioprinted Products by Industry Players: Distribution by Geographical Location of Developers
Table 15.9 3D Bioprinted Products by Industry Players: Distribution by Product Type
Table 15.10 3D Bioprinters by Non-Industry Players: Distribution by Geographical Location of Academia
Table 15.11 3D Bioprinters by Non-Industry Players: Distribution by Development Status
Table 15.12 3D Bioprinted Products by Non-Industry Players: Distribution by Geographical Location of Academia
Table 15.13 3D Bioprinted Products by Non-Industry Players: Distribution by Product Type
Table 15.14 3D Bioprinted Products by Non-Industry Players: Distribution by Development Status
Table 15.15 Organovo: Annual Revenues, 2011- 2017 (USD Million)
Table 15.16 3D Bioprinting Collaborations: Distribution by Year, 2012-2017
Table 15.17 3D Bioprinting Collaborations: Distribution by Type of Model, 2012-2017
Table 15.18 3D Bioprinting Collaborations: Most Active Players, 2012-2017
Table 15.19 3D Bioprinting Funding Instances: Distribution by Type of Funding, 2012-2017
Table 15.20 3D Bioprinting Funding Instances: Distribution by Total Amount Invested, 2012-2017 (USD Million)
Table 15.21 3D Bioprinting Funding Instances: Most Active Players, 2012-2017
Table 15.22 3D Bioprinting Patents: Distribution by Publication Type
Table 15.23 3D Bioprinting Patents: Distribution by Publication Year
Table 15.24 3D Bioprinting Patents: Distribution by Year and Regions
Table 15.25 3D Bioprinting Patents: Leading Assignees
Table 15.26 3D Bioprinting Patents: Geographical Distribution of Leading Assignees
Table 15.27 3D Bioprinting Market: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
Table 15.28 3D Bioprinting Market: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Table 15.29 3D Bioprinting Market: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
Table 15.30 3D Bioprinting Market: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.31 3D Bioprinting Market: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Table 15.32 3D Bioprinting Market: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.33 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035., Conservative Scenario (USD Billion)
Table 15.34 3D Bioprinting Market: Distribution by Applications, 2020, 2029 and 2035, Base Scenario (USD Billion)
Table 15.35 3D Bioprinting Market: Distribution by Applications 2020, 2029 and 2035, Optimistic Scenario (USD Billion)
Table 15.36 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Conservative Scenario (USD Billion)
Table 15.37 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Base Scenario (USD Billion)
Table 15.38 3D Bioprinting Market for Drug Testing / Drug Screening: Short-Mid Term (2018-2027), Optimistic Scenario (USD Billion)
Table 15.39 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.40 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Table 15.41 3D Bioprinting Market for Drug Testing / Drug Screening: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.42 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
Table 15.43 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Table 15.44 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
Table 15.45 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Conservative Scenario (USD Billion)
Table 15.46 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Base Scenario (USD Billion)
Table 15.47 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Mid-Long Term (2027-2035), Optimistic Scenario (USD Billion)
Table 15.48 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Conservative Scenario (USD Billion)
Table 15.49 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Base Scenario (USD Billion)
Table 15.50 3D Bioprinting Market for Tissue Engineering / Tissue Implants: Distribution by Tissue Type, 2025, 2030 and 2035, Optimistic Scenario (USD Billion)
Table 15.51 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Conservative Scenario (USD Billion)
Table 15.52 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Base Scenario (USD Billion)
Table 15.53 3D Bioprinting Market for Bioprinted Skin: Short-Mid Term (Till 2027), Optimistic Scenario (USD Billion)
Table 15.54 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Conservative Scenario (USD Billion)
Table 15.55 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Base Scenario (USD Billion)
Table 15.56 3D Bioprinting Market for Bioprinted Skin: Mid-Long Term, (2027-2035), Optimistic Scenario (USD Billion)
Table 15.57 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.58 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.59 3D Bioprinting Market for Bioprinted Cornea: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.60 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.61 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.62 3D Bioprinting Market for Bioprinted Cartilage: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.63 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.64 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.65 3D Bioprinting Market for Bioprinted Bone: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.66 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.67 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.68 3D Bioprinting Market for Bioprinted Blood Vessels: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.69 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.70 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.71 3D Bioprinting Market for Bioprinted Heart Valves: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.72 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.73 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.74 3D Bioprinting Market for Organ Transplants: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.75 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.76 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.77 3D Bioprinting Market for Bioprinted Breast Implants: Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.78 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.79 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.80 3D Bioprinting Market for Bioprinted Kidney: Mid-Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.81 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.82 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.83 3D Bioprinting Market for Bioprinted Liver: Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.84 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Conservative Scenario (USD Billion)
Table 15.85 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Base Scenario (USD Billion)
Table 15.86 3D Bioprinting Market for Bioprinted Heart: Long Term (Till 2035), Optimistic Scenario (USD Billion)
Table 15.87 3D Bioprinting Market: Distribution by Region, 2018-2035, Conservative Scenario (USD Billion)
Table 15.88 3D Bioprinting Market: Distribution by Region, 2018-2035, Base Scenario(USD Billion)
Table 15.89 3D Bioprinting Market: Distribution by Region, 2018-2035, Optimistic Scenario (USD Billion)
Table 15.90 3D Bioprinting Market: Distribution by Technology, 2018-2035, Conservative Scenario (USD Billion)
Table 15.91 3D Bioprinting Market: Distribution by Technology, 2018-2035, Base Scenario (USD Billion)
Table 15.92 3D Bioprinting Market: Distribution by Technology, 2018-2035, Optimistic Scenario (USD Billion)
Table 15.93 3D Bioprinting Market: 2018, 2027 and 2035 (USD Billion)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3D Bioprinting Solutions
  • Danske Bank
  • INSION
  • National Cancer Institute
  • Roche
  • University of Antwerp
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

  • Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the 3D bioprinting market in the mid to long term.
  • Chapter 3 provides a general overview of 3D bioprinting, covering its historical background, evolution and current applications. In addition, the section provides information on the material and technical requirements, and the process of bioprinting.
  • Chapter 4 provides a comprehensive market landscape of 3D bioprinters and bioprinted products that have already been developed and / or are under development. This chapter includes information on the developers, applications, technologies, details on different printing parameters (for instance, cell viability, precision, print speed and resolution) and the cost of bioprinters.
  • Chapter 5 presents profiles of some of the active players (based on the number of bioprinters / commercialized bioprinted products) in this domain, highlighting their expertise related to 3D bioprinters and bioprinted products. Each profile provides a brief overview of the company, 3D bioprinting devices and / or bioprinted products, its financial information (wherever available), recent developments and a comprehensive future outlook.
  • Chapter 6 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst stakeholders in this market. The chapter includes details on the different partnership models, such as research agreements, distribution agreements, product development agreements and licensing agreements that have been established in the period between 2012 and late 2017. In addition, we have presented details on the various investments and grants received by companies between 2012 to late 2017, highlighting the growing interest of the venture capital community and other strategic investors within this market.
  • Chapter 7 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of 3D bioprinting, under a comprehensive SWOT framework.
  • Chapter 8 provides insights on the popularity of 3D bioprinting on the social media platform, Twitter. The section features an analysis of the yearly distribution of tweets posted on the platform in the time period 2012 to late 2017, highlighting the most significant events responsible for the increase / decrease in the volume of tweets each year.
  • Chapter 9 provides insights on recent trends in the 3D bioprinting industry, such as scaffold-free printing, stem cell based bioinks, 4D bioprinting and advent of low-cost bioprinters, which are expected to influence the adoption of bioprinted products in the coming years.
  • Chapter 10 features a comparison of product competitiveness and supplier power of bioprinters in the form of a 2 x 2 matrix. The analysis takes into considerations several parameters such as type of technology and range of applications offered by these bioprinters.
  • Chapter 11 provides a detailed analysis of the patents that have been filed in the field of 3D bioprinting. The analysis highlights emerging trends in the intellectual property portfolio of this field, and identifies the key players that are driving innovation in this space.
  • Chapter 12 presents a comprehensive market forecast analysis, highlighting the future potential of 3D bioprinting, till the year 2035. We have segregated the opportunity on the basis of the type of application of the bioprinted product (drug testing / drug screening, tissue engineering / tissue implants and organ transplant), type of bioprinting technology (extrusion, inkjet, laser and others) and the geographical distribution of the market (North America, Europe, Asia Pacific and Rest of the World). The sales potential and future growth opportunity were estimated based on the target patient population, likely adoption rates and the likely price of products.
  • Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of discussions held with the following individuals:
    1. Douglas Chrisey (Professor, Tulane University)
    2. Fanny Geraldo and Lisa Oliver (Researchers, University of Nantes)
    3. Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences)
    4. Igor Zlatkin (Application Scientist, Digilab)
    5. Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt)
    6. Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices)
    7. Lauralyn McDaniel (Industry Manager, SME)
    8. Marc Thurner (Chief Executive Officer, regenHU)
    9. Roger Narayan (Professor, North Carolina State University)
    10. Simon Fried (Chief Business Officer, Nano Dimension)
  • Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
  • Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.
Note: Product cover images may vary from those shown
5 of 5
  • 3D Bioprinting Solutions
  • 3D Systems
  • 3Dynamic Systems
  • 500 Startups
  • Accellta
  • Advanced Solutions
  • Advanced Solutions Life Sciences
  • Aether
  • Albert Ludwig University of Freiburg
  • AMBER (Advanced Materials and BioEngineering Research)
  • American Process
  • Amuza
  • AO Research Institute Davos (ARI)
  • Aprecia Pharmaceuticals
  • Aquitaine Science Transfert
  • ASI Life Sciences
  • AxolotlBio
  • Axolotl Biologix
  • BASF
  • Belgorod State University
  • BellaSeno
  • Ben Franklin Technology Partners
  • Bio3D Technologies
  • BioAdvance
  • BioBots (Allevi)
  • BioDan Group
  • Bioftalmik
  • Bioink Solutions
  • BioServe Space Technologies
  • Bone Therapeutics
  • Bösing Dental and Implant Solutions
  • Breakout Labs
  • Brigham and Women's Hospital
  • Brunel University London
  • BTI Biotechnology Institute
  • Cambridge University Hospitals
  • Canada Foundation for Innovation (CFI)
  • Captario
  • Cardiovascular Innovation Institute (CII)
  • Carnegie Mellon University
  • Celgene
  • Cell Applications
  • CELLINK
  • Censo Biotechnologies (previously Roslin Cellab)
  • Center for Advancement of Science in Space (CASIS)
  • Center for Gene and Cellular Therapies in the Treatment of Cancer (ONCOGEN)
  • Cerhum
  • Chalmers University of Technology
  • Children’s National Health System
  • China Resources (Holdings)
  • Chinese Academy of Engineering
  • Chungnam National University Hospital
  • Citizens Bank
  • Clemson University
  • Cold Springs Harbor Laboratory
  • Collagen Solutions
  • Columbia University
  • Competence Centre TEDD (Tissue Engineering for Drug Development and Substance Testing)
  • Cornell University
  • Cosmo Bio
  • CPA Group
  • Crain’s Detroit Business
  • Cyfuse Biomedical
  • Danske Bank
  • DBJ Capital
  • DePuy Synthes Companies
  • DiethelmKellerSiberHegner (DKSH)
  • DigiLab
  • DreamIt
  • Drexel University
  • Eli Lilly
  • Embrapa Genetic Resources and Biotechnology's Laboratory of Nanobiotechnology (LNANO)
  • EnvisionTEC
  • EpiBone
  • ETH Zurich
  • European Medicines Agency (EMA)
  • Ewing Marion Kauffman Foundation
  • Fernández-Vega Foundation
  • FLENI
  • Flexadyne
  • Flipkart
  • Foley & Lardner LLP
  • Forschungsinstitut für Leder und Kunststoffbahnen
  • Foundation for the Fight Against Infantile Neurological Diseases
  • Founders Alliance
  • Fraunhofer CMI
  • Friedrich-Alexander-University of Erlangen-Nürnberg
  • FUJIFILM Dimatix
  • FundersClub
  • GeSiM
  • Glidewell
  • GoPrint3D
  • GreenByte AB
  • Greiner Bio-One
  • Hangzhou Electronic Science and Technology University
  • Hannover Medical School
  • Hanyang University
  • Harvard Medical School
  • Health Resources and Services Administration (HRSA)
  • Heart Research Institute
  • Helisys
  • Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  • Heriot-Watt University
  • Hoffmann-La Roche
  • Hogeschool Utrecht
  • Hospital General Universitario Gregorio Marañón
  • Houston Methodist
  • Humane Society International
  • I&L Biosystems
  • Image Analysis
  • INVITRO
  • Indiana University
  • Indiegogo
  • INNOTERE
  • Innovate UK-MoST
  • INSION
  • Institute for Drug Safety Sciences
  • Institute of Burn Research, Southwest Hospital
  • International Society for Biofabrication (IBSF)
  • International Space Station
  • InvestX Capital
  • Invetech
  • IQ ARTISIA
  • Izumi International
  • JAFCO
  • Janssen Research and Development
  • Johns Hopkins University
  • Johnson & Johnson
  • Katholieke Universiteit Leuven
  • Korea Institute of Machinery and Materials (KIMM)
  • Korean Institute of Science and Technology (KIST)
  • Labsun
  • Le Vivier
  • Life Science Nord group
  • L'Oréal
  • Ludwig Maximilian University of Munich
  • Luxexcel
  • Maastricht University
  • Made In Space
  • MakerBot
  • MaRS Innovation
  • Mass Innovation Labs
  • Massachusetts Institute of Technology (MIT)
  • Mayo Clinic
  • McGill University Health Centre
  • McMaster University
  • Medical University of South Carolina
  • Medicrea
  • MedImmune
  • MEDPRIN BIOTECH
  • Med-Tech Innovation
  • Merck & Co
  • Merrill Corporation
  • Metabridge
  • Methuselah Foundation
  • microdrop Technologies
  • MicroFab Technologies
  • MIDSCI
  • Mode Diagnostics
  • Morriston Hospital
  • Moss Enterprises
  • Murdoch Children’s Research Institute (MCRI)
  • MUSC Bioprinting Research Center
  • My Doctor
  • n3D Biosciences
  • Nano Dimension
  • Nanyang Technological University
  • NASA
  • National Cancer Institute
  • National Center for Advancing Translational Sciences (NCATS)
  • National Eye Institute (NEI)
  • National Institutes of Health (NIH)
  • National Medical Research Radiological Centre of the Ministry of Health of the RussianFederation
  • National Research Council-Industry Research Assistance Program (NRC-IRAP)
  • National Science Foundation (NSF)
  • National University of Singapore (NUS)
  • Neatco
  • NetScientific
  • Neutec Group
  • New Ventures BC
  • Newcastle University
  • News/Talk 760 WJR
  • NextGene Biosystem
  • Nike
  • Nippon Venture Capital
  • Northeastern University
  • Northwestern University
  • Novartis
  • nScrypt
  • NSF Frontiers in Integrative Biological Research
  • NSF SBIR
  • Objet Geometries
  • Ohio State University
  • OHSU Knight Cancer Institute
  • Oregon Health & Science University (OHSU)
  • Organovo
  • Ortho Baltic Group
  • Ourobotics
  • Oxford MEStar
  • OxSyBio
  • Pandorum Technologies
  • Pennsylvania State University
  • PeptiGelDesign Technologies
  • Phonak
  • Plum Alley Investments
  • Poietis
  • Praxis Pharmaceutical
  • Precise Bio
  • Pressure BioSciences
  • Princeton University
  • ProtoSpace Foundation
  • Qingdao Unique Products Develop
  • Queensland University of Technology
  • Rainbow Biosciences
  • Range of Motion Project (ROMP)
  • RBC Royal Bank
  • REGEMAT 3D
  • regenHU
  • Regenovo Biotechnology (subsidiary of Shining3D)
  • ReproCELL Group
  • RESAAS Services
  • Research Centre for Energy, Environment and Technology (CIEMAT)
  • Rice University
  • Ricoh
  • Roche
  • Rokit
  • RoosterBio
  • Royan Institute
  • R-Pharm
  • Russian Medical Academy of Postgraduate Education Studies
  • Sahlgrenska Academy
  • Samsara Sciences
  • Sanford Consortium for Regenerative Medicine
  • Sanitas International
  • SAP America
  • SBH Sciences
  • ScanSource
  • Sciperio
  • Scripps Clinic
  • Seoul National University Bundang Hospital
  • Seoul National University of Science and Technology
  • Seraph Robotics
  • Shanghai Jiao Tong University
  • Shanghai Man Heng Digital Technology
  • Shapeways
  • Shibuya Kogyo
  • Sichuan Revotek
  • Siemens
  • Silentys (Zeltia Group)
  • Sirris
  • Skinprint
  • Skolkovo Innovation Centre
  • Solidscape
  • Somos
  • South by Southwest SXSW Accelerator
  • Spanish National Research Council
  • SPIRE Bioventures
  • Stanford University
  • Stem Cell Network
  • Stemorgan Therapeutics
  • SternAegis Ventures
  • Stratasys
  • Sunnybrook Health Sciences Centre
  • SunP Biotech International
  • Swansea University Medical School
  • Swiss Center for Electronics and Microtechnology
  • Symme 3D
  • Tanner Friedman
  • Technical University of Munich (TUM)
  • TeViDo BioDevices
  • The Finnish Funding Agency for Innovation
  • The Scripps Research Institute
  • The Trade & Industry Group of Gothenburg&Co
  • The University of Virginia
  • The Welsh Centre for Burns and Plastic Surgery
  • The Welsh Centre for Printing and Coating
  • ThermoFisher Scientific
  • Tiffany & Co
  • Tissue Engineering and Regenerative Medicine International Society
  • Trideo
  • Tsinghua University
  • Tufts University
  • UMC Utrecht
  • UniQuest
  • United Rocket and Space Corporation
  • Universidad Carlos III de Madrid
  • Université catholique de Louvain
  • University College of London
  • University of Antwerp
  • University of Bath
  • University of Bayreuth
  • University of Bordeaux
  • University of British Columbia
  • University of California
  • University of Cambridge
  • University of Colorado
  • University of Dayton
  • University of Eastern Finland
  • University of Exeter
  • University of Iowa College of Engineering
  • University of Liverpool
  • University of Louisville
  • University of Manchester
  • University of Manitoba
  • University of Maryland
  • University of Minnesota
  • University of Missouri
  • University of North Carolina
  • University of Nottingham
  • University of Otago, Christchurch
  • University of Pennsylvania
  • University of Pisa
  • University of Sheffield
  • University of South Australia (UniSA)
  • University of South Carolina
  • University of Southampton
  • University of Texas at San Antonio (UTSA)
  • University of Tokyo
  • University of Tokyo Edge Capital
  • University of Toronto
  • University of Victoria
  • University of Washington
  • University of Waterloo
  • University of Wollongong
  • University of Zurich
  • University Santiago de Compostela
  • USFDA
  • Utrecht3DMedical (University Medical Center Utrecht)
  • VisualPing
  • Vivos Dental
  • Wake Forest Baptist Medical Center
  • Wake Forest Institute for Regenerative Medicine
  • Wallenberg Wood Science Center
  • Watson Research Center
  • WiSEED
  • Wyss Institute (Harvard University)
  • Xanofi
  • Xilloc
  • Yale School of Medicine
  • Yale University
  • Z Corporation
  • Zeev Bregman
  • Zeltia Group
  • ZenBio
  • Zurich University of Applied Sciences (ZHAW)
  • Zyomic Technologies
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll